Clinical Trial Update: A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) [Phase 1]

View source ↗

Summary

Phase 1 trial of MK-8353 in advanced solid tumors was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• MK-8353

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Tumor, Solid | Phase 1 | Status: TERMINATED | Results posted: 2020-04-02